![Accelerating pharma's sustainability efforts Accelerating pharma's sustainability efforts](https://cdn.magzter.com/1394808148/1730438393/articles/EtURicje31730515966380/ACCELERATING-PHARMAS-SUSTAINABILITY-EFFORTS.jpg)
Integrating ESG considerations into core pharma operations
India, known as the "Pharmacy of the World," produces over 20 per cent of the global supply of generic medicines and plays a vital role in vaccine production, as per the Investindia.gov.in website. It meets the healthcare needs of over 1.4 billion people domestically while providing affordable medicines to over 200 countries, significantly contributing to global public health.
As sustainability gains global focus, India's pharma sector should integrate ESG considerations into its core operations. Only about 20 per cent of companies in the life science and healthcare sector are well-prepared to handle ESG requirements, with around 30 per cent moderately prepared and another 30 per cent somewhat prepared. This indicates that, despite some progress, a significant portion of the sector still needs to elevate its ESG practices, as per an October 2023 report from Deloitte, titled, 'Embedding environmental sustainability into pharma's DNA'.
Embedding sustainability into the core business strategy is essential for long-term success. This includes reducing environmental footprints, ensuring ethical supply chains, fostering inclusive workplaces, and maintaining transparent governance. One key aspect is value-chain sustainability, where initiatives such as the Pharmaceutical Supply Chain Initiative (PSCI) and the Sustainable Medicines Partnership (SMP) play a pivotal role. These initiatives help standardise best practices across the industry, ensuring that sustainability efforts extend beyond the company's operations to include suppliers, manufacturers, and other key stakeholders in the value chain.
This story is from the {{IssueName}} edition of {{MagazineName}}.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber ? Sign In
This story is from the {{IssueName}} edition of {{MagazineName}}.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber? Sign In
![Pharma's strategic path to growth in the nutra maze Pharma's strategic path to growth in the nutra maze](https://reseuro.magzter.com/100x125/articles/5843/1981257/S7RL7urj51738585009245/PHARMAS-STRATEGIC-PATH-TO-GROWTH-IN-THE-NUTRA-MAZE.jpg)
Pharma's strategic path to growth in the nutra maze
The nutraceutical market is a thriving ecosystem of opportunities. For pharma companies, it's a space where the allure of a $11.55 billion pie by 2030 is tempered by a maze of regulatory grey zones, stiff competition, and trust-eroding marketing practices.
![PRIME NEO from Gandhi Automations PRIME NEO from Gandhi Automations](https://reseuro.magzter.com/100x125/articles/5843/1981257/pSoWQPTC11738587385901/PRIME-NEO-FROM-GANDHI-AUTOMATIONS.jpg)
PRIME NEO from Gandhi Automations
Gandhi Automation's PRIME NEO High Speed Doors are designed to provide superior sealing and resistance to pressure differences for clean rooms. And the added advantage is that it is absolutely washable
![AI smart camera for real-time automation AI smart camera for real-time automation](https://reseuro.magzter.com/100x125/articles/5843/1981257/s351jeUlb1738587298023/AI-SMART-CAMERA-FOR-REALTIME-AUTOMATION.jpg)
AI smart camera for real-time automation
Integrated asset management functionality and a deep learning tool for training and evaluation keep productivity high and costs low
![PROSOLV® 730: Directly compressible carrier for lipophilic ingredients PROSOLV® 730: Directly compressible carrier for lipophilic ingredients](https://reseuro.magzter.com/100x125/articles/5843/1981257/6cppB9bi11738586297726/PROSOLV-730-DIRECTLY-COMPRESSIBLE-CARRIER-FOR-LIPOPHILIC-INGREDIENTS.jpg)
PROSOLV® 730: Directly compressible carrier for lipophilic ingredients
Nearly 90% of molecules in the discovery pipeline and 40% of drugs with market approval are poorly water soluble.
![Complete environmental monitoring solution - testo Saveris Pharma Complete environmental monitoring solution - testo Saveris Pharma](https://reseuro.magzter.com/100x125/articles/5843/1981257/TqM5z0Frt1738587594040/COMPLETE-ENVIRONMENTAL-MONITORING-SOLUTION-TESTO-SAVERIS-PHARMA.jpg)
Complete environmental monitoring solution - testo Saveris Pharma
testo Saveris Pharma monitors and documents temperature, humidity, differential pressure, and other parameters without interruption and compliantly with GxP so that audits and inspections are conducted smoothly
![The unmissable Asia healthcare opportunity The unmissable Asia healthcare opportunity](https://reseuro.magzter.com/100x125/articles/5843/1981257/FkJMEHrta1738583001800/THE-UNMISSABLE-ASIA-HEALTHCARE-OPPORTUNITY.jpg)
The unmissable Asia healthcare opportunity
BCG's latest report, The Unmissable Asia Healthcare Opportunity, highlights the region's $5 trillion healthcare market potential by 2030, driven by demographic shifts, investment, and innovation.
![2025: Healthcare and Lifesciences investment outlook 2025: Healthcare and Lifesciences investment outlook](https://reseuro.magzter.com/100x125/articles/5843/1981257/gni4wTlSk1738585367741/2025-HEALTHCARE-AND-LIFESCIENCES-INVESTMENT-OUTLOOK.jpg)
2025: Healthcare and Lifesciences investment outlook
Kapil Khandelwal, Managing Partner, Toro Finserve and EquNev Capital, interprets the possibilities for the various segments of the Indian lifesciences and healthcare sector for this year
![The group's offerings range from over a billion injection doses annually to bespoke medical machinery The group's offerings range from over a billion injection doses annually to bespoke medical machinery](https://reseuro.magzter.com/100x125/articles/5843/1981257/ytLU7DSi51738579961377/THE-GROUPS-OFFERINGS-RANGE-FROM-OVER-A-BILLION-INJECTION-DOSES-ANNUALLY-TO-BESPOKE-MEDICAL-MACHINERY.jpg)
The group's offerings range from over a billion injection doses annually to bespoke medical machinery
Rishad Dadachanji, MD, Dadachanji Group speaks on the company's evolution from a pharma packaging company to a diversified solutions provider in biotechnology, automation, and sterile processing.
![DECODING THE M&A LANDSCAPE DECODING THE M&A LANDSCAPE](https://reseuro.magzter.com/100x125/articles/5843/1981257/m9-U1Nic21738580242970/DECODING-THE-MA-LANDSCAPE.jpg)
DECODING THE M&A LANDSCAPE
Consolidation has emerged as a major trend as the pharma industry seeks new avenues of growth and looks to expand its existing capabilities.
![Evolution and commercialisation of cell and gene therapies Evolution and commercialisation of cell and gene therapies](https://reseuro.magzter.com/100x125/articles/5843/1981257/6TatCW-851738582670742/EVOLUTION-AND-COMMERCIALISATION-OF-CELL-AND-GENE-THERAPIES.jpg)
Evolution and commercialisation of cell and gene therapies
Satyen Sanghavi, Founder & CSO, Regrow Biosciences traces the evolution of cell and gene therapies, highlighting global milestones, industry growth, and reimbursement models.